Published in J Immunotoxicol on April 23, 2012
The metastasis-promoting roles of tumor-associated immune cells. J Mol Med (Berl) (2013) 1.40
Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12
Cancer in the transplant recipient. Cold Spring Harb Perspect Med (2013) 1.06
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92
Dendritic cell-based vaccines: barriers and opportunities. Future Oncol (2012) 0.91
Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90
T-cell modulatory properties of CD5 and its role in antitumor immune responses. Oncoimmunology (2013) 0.87
Ex vivo derived primary melanoma cells: implications for immunotherapeutic vaccines. J Cancer (2013) 0.80
Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression. Cancer Res (2014) 0.80
Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother (2014) 0.80
Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer. Springerplus (2013) 0.79
Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer (2016) 0.79
Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer (2014) 0.78
Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res (2014) 0.77
Melanoma immunotherapy. Cancer Biol Ther (2014) 0.76
Peripheral lymphocyte subset variation predicts prostate cancer carbon ion radiotherapy outcomes. Oncotarget (2016) 0.75
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Main roads to melanoma. J Transl Med (2009) 1.67
EGFR mutational status in penile cancer. Expert Opin Ther Targets (2013) 1.57
Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013) 1.48
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol (2010) 1.45
Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol (2009) 1.45
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
Human melanoma metastases express functional CXCR4. Clin Cancer Res (2006) 1.15
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep (2012) 1.09
Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med (2013) 1.03
Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer (2009) 1.02
Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol (2003) 0.97
Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res (2005) 0.97
Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer (2006) 0.96
Increased HOX C13 expression in metastatic melanoma progression. J Transl Med (2012) 0.95
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J Clin Oncol (2013) 0.92
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med (2013) 0.92
CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol Immunother (2007) 0.91
Expression of the anti-apoptotic protein BAG3 in human melanomas. J Invest Dermatol (2011) 0.91
Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. J Transl Med (2012) 0.88
BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. J Clin Oncol (2004) 0.87
Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer (2011) 0.85
The role of MEK inhibitors in the treatment of metastatic melanoma. Curr Opin Oncol (2014) 0.85
Combination therapy: the next opportunity and challenge of medicine. J Transl Med (2011) 0.85
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study. J Transl Med (2013) 0.84
Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future Oncol (2015) 0.84
Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncol Rep (2011) 0.84
Interleukin 18: friend or foe in cancer. Biochim Biophys Acta (2013) 0.83
The role of optical radiations in skin cancer. ISRN Dermatol (2013) 0.81
Integrating first-line treatment options into clinical practice: what's new in advanced melanoma? Melanoma Res (2015) 0.80
Novel approaches in melanoma prevention and therapy. Cancer Treat Res (2014) 0.80
NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. J Transl Med (2012) 0.80
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med (2014) 0.80
Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations. BMC Cancer (2013) 0.79
Clinical and dermoscopic criteria related to melanoma sentinel lymph node positivity. Anticancer Res (2007) 0.79
Mutation analysis of candidate genes in melanoma-prone families: evidence of different pathogenetic mechanisms at chromosome 9P21. Melanoma Res (2003) 0.79
Lean oncology: a new model for oncologists. J Transl Med (2012) 0.79
Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls. BMC Dermatol (2009) 0.78
Molecular classification of patients with malignant melanoma for new therapeutic strategies. J Clin Oncol (2007) 0.78
Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Res (2003) 0.78
Unexpected distribution of cKIT and BRAF mutations among southern Italian patients with sinonasal melanoma. Dermatology (2013) 0.78
Update on PEG-interferon α-2b as adjuvant therapy in melanoma. Anticancer Res (2012) 0.78
Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. J Chemother (2013) 0.78
Cosmic radiation and cancer: is there a link? Future Oncol (2015) 0.77
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. J Transl Med (2015) 0.77
Discrepant alterations in main candidate genes among multiple primary melanomas. J Transl Med (2014) 0.77
Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. Tumori (2014) 0.77
Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer (2006) 0.76
Who benefits most from adjuvant interferon treatment for melanoma? Am J Ther (2015) 0.76
MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 0.76
Mutations in ERBB4 may have a minor role in melanoma pathogenesis. J Invest Dermatol (2013) 0.75
Vemurafenib beyond progression in a patient with metastatic melanoma: a case report. Anticancer Drugs (2015) 0.75
Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer. Cancer Immunol Immunother (2012) 0.75
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010. Cancer Immunol Immunother (2011) 0.75
A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Res (2017) 0.75
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009. Cancer Immunol Immunother (2010) 0.75
Marker utility for combination therapy. Methods Mol Biol (2014) 0.75
Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma. Eur J Echocardiogr (2011) 0.75
Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008. Cancer Immunol Immunother (2009) 0.75